Erasca Accelerates Pancreatic Cancer Study After Encouraging Monotherapy, Combination Results
Vandana Singh 7 hours ago
Trading IdeasMoversNewsGeneralBiotechHealth CareLarge Cap
Erasca reports strong Phase 1 tumor responses for ERAS-0015 and ERAS-4001 and accelerates its Phase 3 pancreatic cancer trial to early 2027.
Clinical-stage precision oncology company Erasca Inc. (NASDAQ:ERAS) on Friday shared updated U.S. Phase 1 monotherapy and initial combination results for its pan-RAS molecular glue ERAS-0015.
The company also released early Phase 1 monotherapy data for pan-KRAS inhibitor ERAS-4001.
• What is going on currently with ERAS stock?
Following the results, the company accelerated its planned Phase 3 trial in first-line pancreatic cancer to the first half of 2027.
Monotherapy Responses Across Solid Tumors
In the AURORAS-1 trial evaluating pharmacologically active doses of 16 mg to 32 mg once daily across 122 patients, ERAS-0015 monotherapy drove confirmed objective response rates (ORR) across multiple KRAS G12X cancers.
At the 32 mg daily dose, all responding patients across every tumor type remained on treatment.
In second-line or later pancreatic ductal adenocarcinoma (PDAC), ERAS-0015 achieved a 44% confirmed ORR among 25 patients, including a 69% confirmed ORR in 13 patients carrying KRAS G12D or G12V mutations.
Meanwhile, second- or third-line non-small cell lung cancer (NSCLC) patients posted a 60% confirmed ORR at 32 mg daily, and first-line or later biliary tract cancer patients reached a 75% confirmed ORR.
Favorable Tolerability and Combination Potential
ERAS-0015 maintained a favorable safety profile with mostly low-grade treatment-related adverse events and zero dose-limiting toxicities.
Among 54 patients receiving 32 mg daily, adverse events led to zero treatment discontinuations and a 100% median relative dose intensity.
Early combination studies pairing ERAS-0015 with gemcitabine plus nab-paclitaxel, pembrolizumab, or panitumumab also showed favorable tolerability without unexpected safety signals.
Notably, the panitumumab combination generated multiple responses in KRAS G12X colorectal cancer patients.
ERAS-4001 Data and 2027 Clinical Milestones
Separately, initial Phase 1 results for ERAS-4001 showed predominantly low-grade adverse events, zero adverse event-related discontinuations, encouraging pharmacokinetics, and early antitumor activity.
Nonclinical models also confirmed synergistic activity when combining ERAS-0015 and ERAS-4001.
Looking ahead, Erasca plans to launch a potentially registration-enabling trial in second-line or later NSCLC and a Phase 3 trial in first-line PDAC in the first half of 2027.
The company also targets a Phase 3 first-line NSCLC study between late 2027 and early 2028, plus an ERAS-0015 and ERAS-4001 combination escalation trial in 2027.
ERAS Price Action: Erasca shares were down 3.06% at $13.79 at publication on Friday morning, according to Benzinga Pro data.
Image via Shutterstock
See More: Top Momentum Stocks
